2022 - Present | Chief of Breast Medical Oncology, Baptist Health South Florida ‐ Miami Cancer Institute | |
|
||
2019 - 2021 | Breast Program Director, Deerfield Beach | |
|
||
2019 - 2021 | Director of Community Outreach, University of Miami ‐ Sylvester Cancer Center | |
|
||
2010 - 2021 | Associate Professor of Medicine / Co-Leader of Breast Cancer Site Disease Group, University of Miami ‐ Miller School of Medicine | |
|
||
2007 - 2017 | Physician, Boca Raton Regional Hospital | |
|
||
2007 - 2010 | Hematologist/Medical Oncologist / Director of Clinical Research, Boca Raton Regional Hospital ‐ Boca Raton Comprehensive Cancer Center | |
|
||
2007 - 2010 | Physician, West Boca Hospital | |
|
||
2007 - 2010 | Physician, Delray Hospital | |
|
||
1995 - 1997 | Emergency Medical Technician, Rocky Hill Ambulance Association | |
|
||
1995 - 1997 | Research Assistant, University of Connecticut ‐ Health Center | |
|
||
1994 - 1995 | Research Assistant, Massachusetts General Hospital | |
|
||
1989 - 1994 | Pharmaceutical Technician, Cromwell Pharmacy | |
|
Disciplines
Research Interests
Grants
2021 - 2022 | Multimodal and temporal deep learning for designing optimal breast cancer treatment plans. |
University of Miami, Sylvester Comprehensive Cancer Center | |
Sylvester CCSG Big Idea Award | |
Role: Co-investigator | |
Colleague(s): Principle Investigator: Mohamed Abdel-Mottaleb | |
2017 - 2021 | Prospective Observational Study of Mobile App-Based Patient-Reported Outcomes in Advanced Breast Cancer |
Pfizer | |
Role: Principal Investigator | |
2016 - 2020 | A Phase I/II Study to evaluate the safety and efficacy of vinorelbine with trastuzumab emtansine in pre-treated HER2-positive metastatic breast cancer |
University of Miami, Sylvester Comprehensive Cancer Center | |
Role: Principal Investigator | |
2016 - 2020 | Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry (IMPACt) |
Agendia | |
Role: Principal Investigator | |
2015 - 2019 | A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) Plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women with Hormone Receptor-Positive, Her 2-Negative Locoregionally Recurrent or Metastatic Breast Cancer with No Prior Systemic Therapy in this Disease Setting. |
Lily | |
Role: Principal Investigator | |
2014 - 2019 | NSABP B-55: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy |
NSABP | |
Role: Principal Investigator | |
2015 - 2018 | MONA-7: A Phase III Randomized, Double-blind, placebo-controlled study of MONA-7: LEE011 or Placebo in Combination with Tamoxifen and Goserelin or a Non-Steroidal Aromatase Inhibitor (NSAI) and Goserelin for the Treatment of Premenopausal Women with Hormone Receptor Positive, HER 2-Negative, Advanced Breast Cancer |
Novartis | |
Role: Principal Investigator | |
2014 - 2018 | Multicenter, randomized, doubleblinded, placebo controlled, phase 3 trial of Fulvestrant (Faslodex) with or without PD0332991 (Palbociclib) Goserelin in women with hormone receptor positive, Her2 2 Negative metastatic breast cancer whose disease progressed after prior endocrine therapy |
Pfizer | |
Role: Principal Investigator | |
2014 - 2017 | A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673) Administered to Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer |
Medivation | |
Role: Principal Investigator | |
2013 - 2017 | BioMarin 301: A Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of BMN 673 versus Physician's Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer, Who have Received No More than 2 Prior Chemotherapy Regimens for Metastatic Disease |
Biomarin, Medivation/Pfizer | |
Role: Principal Investigator | |
2013 - 2017 | TRIO22/Paloma-2: A Randomized, Multicenter, Double-Blind Phase 3 Study of PD-0332991 (Oral CDK 4/6 Inhibitor) Plus Letrozole Versus Placebo Plus Letrozole for the Treatment of Postmenopausal Women With ER (+), HER2 (-) Breast Cancer Who Have Not Received Any Prior Systemic Anti-Cancer Treatment for Advanced Disease |
Pfizer | |
Role: Principal Investigator | |
2010 - 2016 | PARP Inhibition After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer on ER/PR, HER2 Negative with Known BRCA 1/2 Mutations: Hoosier Oncology Group BRE09146 |
Hoosier Oncology Group (HOG) | |
Role: Principal Investigator | |
2011 - 2015 | A Phase III randomized, multicenter, two arm, open label trial to evaluate the efficacy of TDM1 compared with treatment of physician’s choice in patients with HER 2 positive metastatic breast cancer who have received at least two prior regimens of HER2 directed therapy |
Genentech/Roche | |
Role: Principal Investigator | |
2011 - 2015 | Mavericc: A randomized phase II study of Bevacizumab/mFolfox6 vs. Bevacizumab/FOLFIRI with biomarker stratification in patients with previously untreated metastatic colorectal cancer |
Genentech/Roche | |
Role: Principal Investigator |
Professional Service and Affiliations
2020 - Present | Member, American Cancer Society, ResearcHERS Medical Advisory Board | 2019 - Present | Member, Living Beyond Breast Cancer Medical Advisory Board | 2017 - Present | Member, Florida Society of Clinical Oncology (FLASCO) Board of Directors | 2016 - Present | Breast Cancer Editorial Board, Practice Updates (Elsevier Science) | 2007 - Present | American Board of Internal Medicine, Member | 2004 - Present | Member, American Society of Clinical Oncology | Present | Ad Hoc Journal Reviewer, Journal of Clinical Oncology, Lung Cancer, Future Oncology | 2018 - 2021 | Institutional Representative University of Miami, CARE Consortium | 2018 - 2021 | Institutional Representative University of Miami, National Surgical Adjuvant Breast and Bowel Project (NSABP) | 2016 - 2021 | Editorial Board Member, The Breast Journal | 2014 - 2021 | Member, University of Miami Data Safety Monitoring Committee | 2016 - 2019 | Steering Committee Member, ASCO Quality Oncology Practice Initiative (QOPI) | 2014 - 2019 | Member, University of Miami Clinical Trials Acceleration Grant Review Committee | 2016 - 2018 | Member, Breast Committee Group, Eastern Cooperative Oncology Group (ECOG) | 2016 - 2017 | Member, American Cancer Society, Physician Board | 2015 - 2016 | Peer reviewer, PRIME Monographs | 2014 - 2015 | Committee Chief, University of Miami GYN Cytology Search Committee | 2008 - 2010 | Speaker, FORCE. Facing Our Risk of Cancer Empowered. Organization | 2008 - 2010 | Speaker, Gilda's Club. Cancer Emotional and Social support organization | 2009 - 2009 | Associate Guest Editor, Clinical Therapeutics |
Honors and Awards
- Sigma Phi Honor Society, 1997
- Graduated with High Honor (Mount Holyoke College), 1994
- Howard Hughes Research Fellowship, 1994 – 1995
2004 - 2007 | Fellow, St.Vincents Catholic Medical Center | |
|
||
2002 - 2004 | Resident, St.Vincents Catholic Medical Center | |
|
||
2001 - 2002 | Internship, Yale University ‐ Greenwich Hospital | |
|
||
June 2001 | Doctor, Osteopathic Medicine, University of New England | |
|
||
June 1997 | Master of Science, Neuroscience, University of Connecticut | |
|
||
May 1994 | Bachelor of Arts, Neuroscience, Mount Holyoke College | |
|
Contact Information
Miami Cancer Institute
1228 South Pine Island Road, Suite 410
Plantation, FL 33324
Find a Doctor Profile / Dr. Reshma Mahtani